ARCHIVES

Clinical Trial Pathology Improvements Recommended By Group Remaining Actions After Merit Review

This article is from The Cancer Letter archive.

Vol. 05 No. 02 | January 12, 1979

Download PDF Visit The Full Archive

Related Articles

NCI Faces Major Cuts On Gramm-Rudman Sequestration; Grants, Centers, Trials Slashed

November 3, 1989

Skipper’s Impact: Drugs Curing 40,000 a Year

March 27, 1981

ASCO Guideline Aims To Improve Hormone Receptor Testing

April 23, 2010

Lung Cancer Size May Not Indicate Severity Of Disease

March 29, 2002

Virus Studies Approved By DCE Board for $2.5 Mil. In First Year

November 3, 1989

UPCI Clarifies Agreement Between Eli Lilly And PCRN.

July 27, 2001